SeaX leads $1.65M pre-seed for cardiac wearable startup Skribe
What's the deal? Skribe MedicalDealroom has a profile for this one. Try Dealroom →, a US startup developing wearable cardiac monitoring for cancer patients, has raised a $1.65 million pre-seed round led by SeaX VenturesDealroom has a profile for this one. Try Dealroom →, with participation from GoAhead VenturesDealroom has a profile for this one. Try Dealroom → and Marin Sonoma Impact VenturesDealroom has a profile for this one. Try Dealroom →. The funding has supported technology development and clinical research.
What's the endgame? Skribe's Aurora system combines a multi-sensor adhesive patch with AI analysis to estimate left ventricular ejection fraction, a measure of how well the heart pumps blood. The company wants to replace repeated echocardiograms — which require separate appointments and can delay treatment — with a point-of-care check that fits into oncology visits, and eventually home monitoring.
Why now? Some cancer therapies leave survivors with heart damage, a complication known as Cancer Therapy-Related Cardiac Dysfunction. Skribe said Aurora was selected for the FDA's READI-Home Innovation Challenge, a program aimed at reducing readmissions through home-use devices. Participation offers early regulatory feedback but does not amount to marketing authorization.
The company reports that more than 800 patients have enrolled in its NOECHO study across 10 US sites and one in Southeast Asia, comparing its measurements against echocardiography. SeaX helped arrange hospital collaborations in the region and supported recruitment of more than 100 patients.
What could go wrong? Research published this year describes continuous monitoring and AI as promising for detecting cancer-related heart damage, but says evidence remains limited and needs stronger validation. Echocardiography remains the benchmark, and Skribe still has to prove its wearable can match it.
Skribe was founded by chief executive officer Ryan Neely, chief technology officer Josh Kay, and chief scientific officer Andrew Bohannon. The team previously worked together at iota Biosciences, the wireless bioelectronics company acquired by Astellas PharmaDealroom has a profile for this one. Try Dealroom →.
The signal: At $1.65 million, this is a modest early-stage bet, and its significance lies less in the size than in whether Skribe can produce credible clinical evidence and fit its technology into oncology care. The round reflects growing interest in wearables for a clinically important but still unproven use.
Read more: techinasia.com
Image credit: Generated with Gemini
